Use of Hydroxychloroquine in Combination With Statins as an LDL Lowering Agent in Patients of Type Ii Dm With Diabetic Nephropathy

Abstract

BACKGROUNDStatins have established themselves as one of the best choice for lowering LDL levels, and have recently been proved efficacious for reducing albuminuria significantly. However, with the latest bar for target LDL levels set at 50 mg/dl, we definitely need to look for other ways of lowering LDL especially in population of Diabetics Nephropathy who are not only at high risk for CV mortality but also need dosage reduction due to impaired renal function. With the recent DGI approval of HCQS (hydroxychloroquine) for use as an antidiabetic drug, we decided to explore the effects of HCQS in combination with atorvastatin on Lipid profile of patients with Diabetic Nephropathy. Our study showed that combining HCQS with Atorvastatin results in even better control of LDL levels with favourable effect on other lipids as well.